Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:23:39 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



Q:MNKD - MANNKIND CORPORATION - http://www.mannkindcorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNKD - Q0.13.94·4.880.14.34-0.015-0.3    5.75  3.17May 01May 0115 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-01 16:00U:MNKDNews ReleaseMannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
2024-04-30 06:05U:MNKDNews ReleaseMannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
2024-04-29 06:05U:MNKDNews ReleaseMannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
2024-04-03 06:00U:MNKDNews ReleaseMannKind Repays Certain Debt Obligations
2024-03-26 16:05U:MNKDNews ReleaseMannKind Announces CFO Transition
2024-03-11 06:05U:MNKDNews ReleaseINHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza(TM) Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
2024-03-05 06:05U:MNKDNews ReleaseMannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
2024-03-04 13:01U:MNKDNews ReleaseMannKind Corporation Announces Participation at Upcoming Conferences
2024-02-27 16:00U:MNKDNews ReleaseMannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
2024-02-20 06:00U:MNKDNews ReleaseMannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
2024-02-15 06:05U:MNKDNews ReleaseMannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza ‚ ®
2024-01-02 06:05U:MNKDNews ReleaseMannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
2023-12-28 06:00U:MNKDNews ReleaseMannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07 16:00U:MNKDNews ReleaseMannKind Corporation Reports 2023 Third Quarter Financial Results
2023-11-06 06:15U:MNKDNews ReleaseMannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
2023-10-31 16:00U:MNKDNews ReleaseMannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
2023-10-30 06:15U:MNKDNews ReleaseMannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
2023-09-05 06:00U:MNKDNews ReleaseMannKind Corporation Announces Participation at Upcoming Conferences
2023-08-07 16:00U:MNKDNews ReleaseMannKind Corporation Reports 2023 Second Quarter Financial Results
2023-08-01 06:00U:MNKDNews ReleaseMannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference